Wilson's Disease Diagnosis and Treatment

Diagnostic Criteria

• The American Association for the Study of Liver Diseases recommends that serum copper may be elevated in acute liver failure due to Wilson's disease, typically indicating a need for further diagnostic evaluation 1
• Hepatic copper concentration >250 μg/g dry weight on liver biopsy is confirmatory of Wilson's disease, as stated by the American Association for the Study of Liver Diseases 1, 2
• Kayser-Fleischer rings support the diagnosis but may be absent in up to 50% of patients with acute liver failure due to Wilson's disease, according to the American Association for the Study of Liver Diseases 2, 3
• Low serum alkaline phosphatase and ratio of alkaline phosphatase to total bilirubin <2 is characteristic in acute liver failure due to Wilson's disease, as noted by the American Association for the Study of Liver Diseases 1, 2

Special Clinical Scenarios

• Wilson's disease should be considered in pediatric patients with autoimmune hepatitis-like presentation, as recommended by the American Association for the Study of Liver Diseases 1, 2
• The American Association for the Study of Liver Diseases suggests that Wilson's disease should be considered in adults with atypical autoimmune hepatitis or poor response to corticosteroid therapy 1, 2
• Patients with acute liver failure with Coombs-negative intravascular hemolysis should be evaluated for Wilson's disease, according to the American Association for the Study of Liver Diseases 1, 2

Family Screening

• First-degree relatives of patients with Wilson's disease must be screened, as recommended by the American Association for the Study of Liver Diseases 1, 4
• Screening should include history and physical examination, serum copper and ceruloplasmin, liver function tests, and slit-lamp examination for Kayser-Fleischer rings, as stated by the American Association for the Study of Liver Diseases 1, 4, 5, 6

Treatment Options

• The American Association for the Study of Liver Diseases recommends liver transplantation as the only effective treatment option for acute liver failure due to Wilson's disease 1, 7
• Treatment should be initiated for all individuals greater than 3 years old identified through family screening, with either zinc or a chelating agent effective in preventing disease progression, as noted by the American Association for the Study of Liver Diseases 1, 7, 4
• Zinc appears preferable for presymptomatic children under the age of 3 years, according to the American Association for the Study of Liver Diseases 7

Monitoring Treatment

• Patients should be monitored at least twice yearly, with laboratory testing including liver function tests, indices of copper metabolism, and 24-hour urinary copper excretion, as recommended by the American Association for the Study of Liver Diseases 1, 7, 4, 5
• Target values for patients on chelators include 24-hour urinary copper excretion of 200-500 μg/day, and for patients on zinc, urinary copper excretion no more than 75 μg/day, as stated by the American Association for the Study of Liver Diseases 7, 5

Common Pitfalls and Caveats

• Combination treatment with chelator plus zinc requires careful timing to avoid having the chelator bind to zinc, as noted by the American Association for the Study of Liver Diseases 7
• Overtreatment can lead to copper deficiency, resulting in neutropenia, anemia, and hyperferritinemia, according to the American Association for the Study of Liver Diseases 7, 5
• Treatment must be maintained throughout pregnancy, as interruption during pregnancy has resulted in acute liver failure, as recommended by the American Association for the Study of Liver Diseases 7

Diagnostic Approach and Management of Wilson Disease

Diagnostic Considerations

• The American Association for the Study of Liver Diseases recommends considering Wilson disease in individuals aged 3-55 years with liver abnormalities of uncertain cause, as well as those with unexplained liver disease combined with neurological or neuropsychiatric symptoms 8, 9
• The presence of Kayser-Fleischer rings, although not exclusive to Wilson disease, is a significant diagnostic indicator, and their absence does not exclude the disease, especially in neurological presentations 8, 9
• Serum ceruloplasmin levels are typically low in Wilson disease, but can be falsely elevated by inflammation, pregnancy, estrogen supplementation, or oral contraceptives, and immunologic assays may overestimate levels 8, 9
• The American Association for the Study of Liver Diseases suggests that serum aminotransferase elevations may be mild and do not reflect disease severity 8, 9

Management and Treatment

• The European Association for the Study of the Liver recommends that all diagnosed patients require lifelong treatment, which must be initiated immediately upon diagnosis, and presymptomatic patients identified through family screening should start treatment to prevent disease progression 8, 9
• The American Association for the Study of Liver Diseases suggests that zinc salts, such as zinc acetate, are effective for maintenance therapy in presymptomatic patients and those with less severe disease, and must be taken at least 30 minutes before meals for optimal absorption 8
• Chelating agents, such as D-penicillamine, are also effective, but may worsen neurological symptoms during initiation, and require careful monitoring 8, 9

Wilson Disease Diagnostic Work‑up Guidelines

Initial Diagnostic Approach

• Diagnosis relies on a constellation of clinical, laboratory, and imaging findings rather than a single definitive test, according to expert consensus. 10, 11

Laboratory Evaluation

• First‑line serum studies should include ceruloplasmin, copper, aminotransferases, bilirubin, albumin, INR, and a complete blood count to detect hemolytic anemia; these tests together provide essential screening information. 10, 12, 13

• A 24‑hour urinary copper excretion >100 µg/day supports Wilson disease and should be obtained early in the work‑up. 10, 12, 13

• Non‑ceruloplasmin‑bound copper can be calculated from serum copper and ceruloplasmin values to aid interpretation when direct measurements are unavailable. 14

Physical Examination

• Slit‑lamp examination by an experienced ophthalmologist is mandatory; Kayser‑Fleischer rings are present in nearly all patients with neurological manifestations of Wilson disease. 11

Fulminant Hepatic Failure Indicators

• In patients with acute liver failure, the following pattern strongly suggests Wilson disease:

Autoimmune Hepatitis‑like Presentation

• All pediatric patients presenting with autoimmune hepatitis should be screened for Wilson disease. 10, 12

• Adults with atypical autoimmune hepatitis features or poor response to corticosteroids must be evaluated for Wilson disease before continuing immunosuppression. 10, 12

Other Hepatic Presentations

• Wilson disease should be considered in patients with non‑alcoholic fatty liver disease or non‑alcoholic steatohepatitis on histology. 10, 12

• Isolated splenomegaly or unexplained hepatomegaly warrants evaluation for Wilson disease. 11

Age Considerations

• Although traditionally described in younger individuals, Wilson disease can be diagnosed from age 3 up to the eighth decade of life, with documented cases in patients aged 55–62 years. 11

Family Screening Protocol

• All first‑degree relatives of a newly diagnosed patient must undergo screening, which includes:

• Relatives lacking Kayser‑Fleischer rings but showing subnormal ceruloplasmin and abnormal liver tests should proceed to liver biopsy for definitive confirmation. 10, 13

Early Diagnosis and Treatment Initiation

• Presymptomatic individuals identified through family screening who receive therapy have an excellent long‑term prognosis and rarely develop clinical manifestations. 14

• Treatment should be started immediately upon diagnosis in all individuals older than 3–4 years. 10, 12

Screening and Management of First‑Degree Relatives of Wilson’s Disease Patients

Who Should Be Screened

• All first‑degree relatives of a newly diagnosed Wilson’s disease (WD) patient require immediate comprehensive screening; siblings carry a 25 % risk of being affected, and early treatment averts all disease manifestations and yields near‑normal life expectancy. [15][16]17
• Siblings have a 25 % probability of homozygosity for pathogenic ATP7B mutations. [15][17]
• Children of an index case have an approximate 0.5 % risk of disease, justifying screening because untreated disease is devastating. [15][17]

Primary Screening Protocol

• A complete biochemical and clinical evaluation of every first‑degree relative should include:

• When a relative lacks Kayser‑Fleischer rings but shows subnormal ceruloplasmin and abnormal liver tests, a liver biopsy with quantitative hepatic copper measurement should be performed; hepatic copper > 250 µg/g dry weight confirms WD. 16

Genetic Testing Strategy

• If the index patient’s ATP7B mutation(s) are identified, screen relatives for those specific mutations. [15][18]
• If the index mutations are unknown, conduct haplotype analysis using polymorphisms surrounding ATP7B, requiring DNA from both parents and the index patient. [15][17]18
• Genetic testing is the only reliable method to definitively differentiate heterozygous carriers from affected homozygous/compound‑heterozygous siblings. [15][17]

Treatment Initiation

• All relatives confirmed to have WD and older than 3–4 years should start therapy immediately; early treatment prevents disease manifestations entirely in presymptomatic patients and ensures an excellent long‑term prognosis. 16

• For presymptomatic or mildly affected individuals, either maintenance‑dose chelation or zinc therapy is effective:

Long‑Term Prognosis

• Cohort follow‑up of presymptomatic patients identified through family screening and maintained on lifelong therapy for >30 years demonstrates complete prevention of disease symptoms and near‑normal life expectancy. 16